Companion Diagnostics Market Outlook

The global companion diagnostics market is predicted to garner a revenue of about US$ 10560.0 million by 2033, up from US$ 5371.9 million in 2023, with a CAGR of 7.0% during the forecast period.

Companion diagnostics are utilized to ascertain who would benefit from treatment. The market growth for companion diagnostics is propelled by technological advancements, which have brought many changes in the disease treatment method.

Companion diagnostics is characterized by the growing requirement for enhanced personalized patient treatment. It gives healthcare providers and their patients assurance about the treatment results in a positive way, contrary to traditional treatment procedures, positively impacting the companion diagnostics market outlook.

The rise in tailored medicine usage, in tandem with rising demand for targeted therapies, contributes to creating customized CDx and expanding the market size for companion diagnostics.

The advantages of CDx tests, such as their high sensitivity, affordability, and ability to produce accurate results quickly, push the expansion of the companion diagnostics market. It is now well-accepted that medications can interact differently with different people due to advancements in genetic sequencing and genomics.

Pharmaceutical and biopharmaceutical companies continuously work to adopt patient-selection diagnostic frameworks in the early stages of drug development to give focused therapeutics to the appropriate candidate. The same is anticipated to push forward the adoption of companion diagnostics to a considerable extent over the forecast period.

Companion Diagnostics Industry (From 2018 to 2022)

Attribute Details
CAGR 4.5%
Market Size - 2018 US$ 4258.27 million
Market Size - 2022 US$ 5089.2 million

Companion Diagnostics Industry (From 2023 to 2033)

Attribute Details
CAGR 7%
Market Size - 2023 US$ 5371.9 million
Market Size - 2033 US$ 10560.0 million

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Charting Progress: Companion Diagnostics' Ascension from 2018 to the 2033 Frontier

The period from 2018 to 2022 witnessed significant advancements in the companion diagnostics market, marked by increased integration with targeted therapies and personalized medicine. These years saw a growing emphasis on biomarker identification and molecular testing, shaping treatment strategies.

Unprecedented innovation in genomics, AI, and data analytics is set to revolutionize companion diagnostics as we enter the booming era from 2023 to 2033. Anticipated trends include enhanced point-of-care diagnostics, expanded applications in oncology, neurology, and infectious diseases, and the integration of non-invasive monitoring techniques.

Strong collaborations between pharmaceutical and diagnostic companies, regulatory facilitation, and patient-centric healthcare models may fuel market expansion for companion diagnostics. In addition, the next decade promises transformative advancements, propelling companion diagnostics into an integral role within the broad landscape of precision medicine.

Tech Updates 2023: The Evolution of Modern Technologies

The next-generation sequencing-based companion diagnostic tests aim to coordinate treatment choices for disease medications by opening nuclear information from each persistent development genome. Compared to previous sequencing methodologies, front-end sequencing detects various biomarkers for diverse medicines in less time.

Utilizing NGS sheets for biomarker assessment in a single test may aid in treating various ailments. Many creative levels of advancement in NGS give market companies a quick advantage over competitors offering other headways like PCR, ICH, and ISH. The key market players are concentrating on creating amigo illustrative goods while considering NGS.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Biologics on the Rise

Market stability for companion diagnostics is extraordinary. F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc., Qiagen N.V. (Germany), Thermo Fisher Scientific, Inc., and Abbott Laboratories, Inc. are the top competitors in the companion diagnostics market. They represented a combined large part portion of the overall industry in 2020.

There is fierce competition between companies in the companion diagnostics industry. Only large companies can afford high capital investments and the high costs of research and development and production. This prevents the entry of new competitors.

The Dual Challenge of Companion Diagnostics: Limited Awareness and Elevated Costs

Immunotherapy has demonstrated a crucial level of assurance in treating malignant development, but its high cost has hampered widespread access. Also, doctors may decide that it is best to combine treatments. This would extend the treatment's duration from five months to just over three years. The longer the time in this case, the more noticeable the cost.

Personalized immunotherapies are expensive. The cost of disease immunotherapies may be significantly high than other treatment options like chemotherapy or radiation therapy. This is how it is intended that the high price of immuno-oncology treatments may impede the growth of the companion diagnostics market.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Resource Shortage in Emerging Economies

The significance of clinical preliminary examinations must be conveyed to the attention of patients, doctors, and the general public. Also, delivering exceptional access to the recent, reasonable, and well-researched information about these new treatments for malignant growth can aid in expanding physicians' awareness of this issue.

Advancing admittance to a normal and acknowledged truth source is essential to practicing open mindfulness. Also, a few distribution companies and business leaders distribute monthly diaries and data packets.

Partners have focused on awareness campaigns to ensure that patients and suppliers can access and understand the benefits of buddy diagnostics. These factors hamper the market growth for companion diagnostics.

Category- Wise Outlook

Category Technology
Leading Segment Real Time PCR
Market Share 38.0%
Category Product
Leading Segment Assay, Kits & Reagents
Market Share 74.0%

Illuminating Pathways: Real Time PCR's Sales Triumph in Companion Diagnostics Industry

Real time PCR drives significant revenues within the companion diagnostics sector due to its outstanding sensitivity, speed, and accuracy in detecting and quantifying target genetic material. It is the best method for locating specific biomarkers and genetic alterations important for illness diagnosis, prognosis, and therapy decision-making since it allows for real-time monitoring of DNA amplification.

Real time PCR is frequently used because of its quick results and adaptability in examining different sample types. Moreover, real time PCR is crucial in customizing treatments for individual patients as precision medicine gains traction, driving demand.

Real Time PCR is positioned as a key technology in improving personalized medicine and fostering the companion diagnostics market growth due to its strong capacity to identify even minute amounts of target DNA and its automated process.

Regional Outlook

Countries Market CAGR (From 2023 to 2033)
Australia 4.5%
China 9.0%
India 9.8%
The United Kingdom 6.3%

Envisaging North America's Monopolistic Grip on Companion Diagnostics

North America is the leading market, with a share of 27.3% in 2023 due to significant technical inventions and the increasing prevalence of chronic diseases like cancer. The companion diagnostics market trends and forecasts are swayed by the expansion of research activities in this field employing companion diagnostic kits and the growing number of healthcare organizations working on genetic databases created to comprehend the human genome.

Countries Market Share - 2023
North America 27.3%
Europe 21.6%

Upward Trajectory Expected for Europe's Companion Diagnostics Industry

The second-leading market is anticipated to be in Europe, with a market share of companion diagnostics market share of 21.6% in 2023.

A substantial number of businesses are expected to participate as the regional sector expands, and research and development efforts to enhance personalized drug therapy for cancer patients are expected to increase, impacting the regional market. Additionally, rising per capita income increases the desire for individualized care, further promoting consumer development.

Countries Market Share (2023)
The United States 24.0%
Germany 5.1%
Japan 5.6%

Precision Treatment Pathways: Insights into Asia Pacific's Companion Diagnostics Market

Due to rising interest in customized treatment and developments in molecular diagnostics, Asia Pacific’s companion diagnostics industry is projected to expand significantly from 2023 to 2033. Also, the need for companion diagnostics to enable correct therapy selection is growing, with an emphasis on targeted therapeutics.

Market expansion is aided by the region's increasing healthcare infrastructure and partnerships between pharmaceutical and diagnostic companies. The Asia Pacific companion diagnostics market offers key opportunities for both established players and emerging businesses as they work to improve patient outcomes and contribute to the paradigm shift in modern healthcare as regulatory frameworks change, and healthcare spending rises.

Catalyzing Care: Strategic Marketing Strategies for Elevating Companion Diagnostics Adoption

Promoting the companion diagnostics industry requires a strategic approach that combines targeted marketing tactics to reach healthcare professionals, patients, and other stakeholders.

Here are the chief marketing tactics that companion diagnostics manufacturers can utilize to promote the companion diagnostics business:

  • Educational Content Creation:

Develop comprehensive educational content such as whitepapers, case studies, webinars, and articles that explain the importance of companion diagnostics in personalized medicine. Highlight real-life success stories and breakthroughs achieved through the use of companion diagnostics.

  • Thought Leadership and Expertise Building:

Position the manufacturer as a thought leader in companion diagnostics by participating in industry conferences, seminars, and workshops. Present research findings, share insights, and engage in panel discussions to demonstrate the manufacturer's expertise.

  • Collaboration with Key Opinion Leaders (KOLs):

Identify and partner with influential KOLs in the companion diagnostics and personalized medicine fields. Collaborate with these experts to co-create content, participate in webinars, and endorse the manufacturer's products.

  • Engagement with Healthcare Institutions:

Establish strong relationships with hospitals, research institutions, and clinics by offering workshops, training sessions, and continuing medical education (CME) opportunities related to companion diagnostics. Provide support and resources that help healthcare professionals understand how to integrate companion diagnostics into their patient care plans effectively.

  • Patient Advocacy and Support:

Recognize the importance of patient advocacy and support groups in adopting companion diagnostics. Collaborate with patient advocacy organizations to raise awareness about the benefits of personalized medicine and companion diagnostics.

  • Targeted Digital Marketing:

Utilize digital marketing strategies to reach different segments of the target audience. Develop targeted online advertisements, social media campaigns, and search engine optimization (SEO) tactics to ensure that healthcare professionals, patients, and researchers can easily find information about the manufacturer's companion diagnostics offerings.

The key to successful marketing in the companion diagnostics industry is to convey the value of personalized medicine, highlight success stories, and educate both healthcare professionals and patients about companion diagnostics' role in improving patient outcomes.

Start-Up Disruption Sparks Evolution in Companion Diagnostics Market

Numerous start-ups have been founded by many eminent personalities, leaving their mark in the companion diagnostics business, auguring well for its future trends.

Example:

  • For the past 18 years, Ali Ardakani has played a crucial role in the founding and growing of numerous biotech businesses, pharmaceuticals, and medical devices, for which he has raised over US$ 100 million in private and grant funding.
  • His most recent venture was co-founding the virtual biotech start-up Niiki Pharma Inc. in NYC, where he purchased two first-in-class oncology medications from Europe and expedited their development through UK CTA, US IND, and Phase 1 and 2 clinical trials in under three years.

Competitive Landscape

The companion diagnostics industry has several significant competitors, which are highly competitive and fairly fragmented. Key companion diagnostics manufacturers are investing a lot of money in research and development to expand their product portfolios, which is going to compel growth in the companion diagnostics market.

The companion diagnostics manufacturers are taking various strategic actions to expand their global reach, including introducing new products, contract agreements, mergers and acquisitions, increased investments, and partnerships with other businesses. To grow and survive in a more cutthroat and competitive market climate, competitors in the companion diagnostics sector must offer affordable products.

Essential Companion Diagnostics Manufacturers

  • ARUP Laboratories
  • Roche Molecular Systems Inc.
  • Dako Inc.
  • Qiagen Ltd.
  • bioMérieux Inc.
  • Ventana Medical Systems Inc.
  • Abbott Molecular Inc.
  • Myriad Genetics Inc.
  • Biogenex Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • Leica Biosystems Nussloch GmbH
  • Others

Recent Developments

Company Thermo Fisher Scientific
Strategy FDA Greenlights Thermo Fisher's Oncomine Dx Test as Companion Diagnostic for HER2 Mutations
Details Thermo Fisher Scientific's Oncomine Dx Target Test received premarket approval from the United States Food and Drug Administration in August 2022 to be used as a companion diagnostic (CDx) to identify patients with non-small-cell lung cancer whose tumors have HER2 (ERBB2) activating mutations that might be candidates for ENHERTU.
Company Genetron Holdings Limited
Strategy Genetron Holdings and HUTCHMED (China) Partner to Develop Companion Diagnostic
Details Genetron Holdings Limited and HUTCHMED (China) Limited entered into a collaboration agreement to create a companion diagnostic in February 2022. Genetron Holdings Limited is a top precision oncology platform company in China specializing in molecular profiling tests, early cancer screening products, and companion diagnostics development.
Company Amoy Diagnostics Co. Ltd.
Strategy AmoyDx Pan Lung Cancer PCR Panel Launches in Japan
Details The AmoyDx Pan Lung Cancer PCR Panel was introduced in Japan in January 2022 by Amoy Diagnostics Co. Ltd. and PREMIA Holdings (HK) Limited as a reimbursed companion diagnostic for various anti-cancer drugs.

Key Segmentation

By Application:

  • Colorectal Cancer
  • Breast Cancer
  • Lung Cancer
  • Melanoma
  • Urology
  • Gastric Cancer

By Technology:

  • Immunohistochemistry
  • Molecular Diagnostics
  • In-situ Hybridization
  • FISH
  • CISH
  • Real Time PCR
  • Gene Sequencing

By Product:

  • Assay, Kits & Reagents
  • Software and services

By End User:

  • Pharma and Biotech Companies
  • Clinical Research Organizations
  • Reference Laboratories
  • others

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • The Middle East and Africa
  • Europe

Frequently Asked Questions

How much can the Industry Grow by 2033?

The market size of companion diagnostics is estimated to hit US$ 10560.0 million by 2033.

What is the Current Valuation of the Companion Diagnostics Market?

The companion diagnostics industry is to record a valuation of US$ 5371.9 million in 2023.

What is the Growth Outlook of the Companion Diagnostics Market?

The companion diagnostics industry is likely to secure a CAGR of 7% through 2033.

Which are the Key Asian Countries in the Companion Diagnostics Market?

China, Japan, and South Korea are the central Asian countries in the Companion Diagnostics market.

Which Industry is the Key Consumer of the Companion Diagnostics Market?

The pharmaceutical sector is the primary consumer of Companion Diagnostics.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033

        5.3.1. Colorectal Cancer

        5.3.2. Breast Cancer

        5.3.3. Lung Cancer

        5.3.4. Melanoma

        5.3.5. Urology

        5.3.6. Gastric Cancer

    5.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technology

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Technology, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technology, 2023 to 2033

        6.3.1. Immunohistochemistry

        6.3.2. Molecular Diagnostics

        6.3.3. In-situ Hybridization

        6.3.4. FISH

        6.3.5. CISH

        6.3.6. Real Time PCR

        6.3.7. Gene Sequencing

    6.4. Y-o-Y Growth Trend Analysis By Technology, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Technology, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Western Europe

        7.3.4. Eastern Europe

        7.3.5. South Asia and Pacific

        7.3.6. East Asia

        7.3.7. Middle East and Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. The USA

            8.2.1.2. Canada

        8.2.2. By Application

        8.2.3. By Technology

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Application

        8.3.3. By Technology

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Application

        9.2.3. By Technology

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Application

        9.3.3. By Technology

    9.4. Key Takeaways

10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. United Kingdom

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Western Europe

        10.2.2. By Application

        10.2.3. By Technology

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Application

        10.3.3. By Technology

    10.4. Key Takeaways

11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Poland

            11.2.1.2. Russia

            11.2.1.3. Czech Republic

            11.2.1.4. Romania

            11.2.1.5. Rest of Eastern Europe

        11.2.2. By Application

        11.2.3. By Technology

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Application

        11.3.3. By Technology

    11.4. Key Takeaways

12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Bangladesh

            12.2.1.3. Australia

            12.2.1.4. New Zealand

            12.2.1.5. Rest of South Asia and Pacific

        12.2.2. By Application

        12.2.3. By Technology

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Application

        12.3.3. By Technology

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Application

        13.2.3. By Technology

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Application

        13.3.3. By Technology

    13.4. Key Takeaways

14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Application

        14.2.3. By Technology

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Application

        14.3.3. By Technology

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. USA

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Application

            15.1.2.2. By Technology

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Application

            15.2.2.2. By Technology

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Application

            15.3.2.2. By Technology

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Application

            15.4.2.2. By Technology

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Application

            15.5.2.2. By Technology

    15.6. United Kingdom

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Application

            15.6.2.2. By Technology

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Application

            15.7.2.2. By Technology

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Application

            15.8.2.2. By Technology

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Application

            15.9.2.2. By Technology

    15.10. Poland

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Application

            15.10.2.2. By Technology

    15.11. Russia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Application

            15.11.2.2. By Technology

    15.12. Czech Republic

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Application

            15.12.2.2. By Technology

    15.13. Romania

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Application

            15.13.2.2. By Technology

    15.14. India

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Application

            15.14.2.2. By Technology

    15.15. Bangladesh

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Application

            15.15.2.2. By Technology

    15.16. Australia

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Application

            15.16.2.2. By Technology

    15.17. New Zealand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Application

            15.17.2.2. By Technology

    15.18. China

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Application

            15.18.2.2. By Technology

    15.19. Japan

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Application

            15.19.2.2. By Technology

    15.20. South Korea

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Application

            15.20.2.2. By Technology

    15.21. GCC Countries

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Application

            15.21.2.2. By Technology

    15.22. South Africa

        15.22.1. Pricing Analysis

        15.22.2. Market Share Analysis, 2022

            15.22.2.1. By Application

            15.22.2.2. By Technology

    15.23. Israel

        15.23.1. Pricing Analysis

        15.23.2. Market Share Analysis, 2022

            15.23.2.1. By Application

            15.23.2.2. By Technology

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Application

        16.3.3. By Technology

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. ARUP Laboratories

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Roche Molecular Systems Inc.

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Dako Inc.

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Qiagen Ltd.

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. bioMérieux Inc.

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Ventana Medical Systems Inc.

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Abbott Molecular Inc.

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Myriad Genetics Inc.

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Biogenex Laboratories, Inc.

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Thermo Fisher Scientific Inc.

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

        17.1.11. Leica Biosystems Nussloch GmbH

            17.1.11.1. Overview

            17.1.11.2. Product Portfolio

            17.1.11.3. Profitability by Market Segments

            17.1.11.4. Sales Footprint

            17.1.11.5. Strategy Overview

                17.1.11.5.1. Marketing Strategy

        17.1.12. Others

            17.1.12.1. Overview

            17.1.12.2. Product Portfolio

            17.1.12.3. Profitability by Market Segments

            17.1.12.4. Sales Footprint

            17.1.12.5. Strategy Overview

                17.1.12.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Recommendations

Healthcare

Infectious Disease Diagnostics Market

January 2016

REP-GB-1208

June 2024

250 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Companion Diagnostics Market